MRNA · 8-K · 20260708PR000134

Guidance / Outlook

Moderna, Inc. · 2026-07-08 · Importance 23 · Surprise 24 · In source text

Moderna said it intends to continue advancing its mRNA pipeline and executing its long-term strategy following Michael McDonnell’s appointment to the Board, effective July 8, 2026. Management said the company is preparing for multiple potential product launches, but did not provide launch dates, revenue targets, margin guidance, or capital-expenditure amounts. The outlook is forward-looking and depends on the company’s ability to progress its pipeline and commercialize products over the long term.

Key facts

• The press release contains forward-looking statements that include expectations for multiple potential product launches. source
• Moderna stated it is preparing for multiple potential product launches. source
• The press release contains forward-looking statements regarding Moderna's ability to advance its pipeline and execute on its long-term strategy. source

Impact estimates